Abstract
Ulcer complications associated with the use of NSAIDs, in high-risk patients, are often caused by a failure to identify patients' risk factors, concomitant use of aspirin or multiple NSAIDs, and underutilization of gastroprotective agents. Current data suggest that cyclo-oxygenase 2 (COX2) inhibitors and some nonselective NSAIDs increase the risk of myocardial infarction. Physicians must, therefore, take into account both the gastrointestinal and the cardiovascular risks of individual patients when prescribing NSAIDs. In patients with a low cardiovascular risk, NSAIDs can be prescribed according to the level of gastrointestinal risk. Patients with a moderate gastrointestinal risk (one or two risk factors) should receive a COX2 inhibitor or an NSAID plus a PPI or misoprostol. Patients with more than two gastrointestinal risk factors or prior ulcer complications require the combination of a COX2 inhibitor and a PPI. Patients with a high cardiovascular risk (e.g. coronary heart disease or an estimated 10-year cardiovascular risk greater than 10%) should receive prophylactic aspirin and combination therapy with a PPI or misoprostol irrespective of the presence of gastrointestinal risk factors. Naproxen is the preferred NSAID because it is not associated with excess cardiovascular risk. Patients with a high cardiovascular risk and a very high gastrointestinal risk should avoid using NSAIDs or COX2 inhibitors.
Key Points
-
NSAID-induced ulcer complications can be avoided by careful assessment of risk factors before prescription of these drugs
-
In light of the potential cardiovascular risk of COX2-selective and nonselective NSAIDs, physicians must evaluate both the gastrointestinal and the cardiovascular risk profiles of individual patients when prescribing NSAIDs
-
COX2 inhibitors alone, or nonselective NSAIDs plus a PPI, do not provide adequate gastric protection to patients with a very high gastrointestinal risk
-
Physicians can assess the cardiovascular risk of individual patients by use of the Framingham risk-score calculator
-
Patients with a high cardiovascular risk who require NSAIDs should receive prophylactic aspirin and combination therapy with a PPI or misoprostol
-
Naproxen is the preferred NSAID in patients with high cardiovascular risk
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Silverstein FE et al. (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284: 1247–1255
Lanas A et al. (2005) A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am J Gastroenterol 100: 1685–1693
Laine L et al. (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124: 288–292
Allison MC et al. (1992) Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 327: 749–754
Singh G and Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26 (Suppl): 18–24
Cryer B (2005) NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am J Gastroenterol 100: 1694–1695
Langman MJ et al. (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 1075–1078
Garcia Rodriguez LA and Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769–772
Griffin MR et al. (1991) Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114: 257–263
Gabriel SE et al. (1991) Risks for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 115: 787–796
Silverstein FE et al. (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123: 241–249
Henry D et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312: 1563–1566
Huang JQ et al. (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359: 14–22
Chan FK et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110
Chan FK et al. (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244
Boissonnault WG and Meek PD (2002) Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. J Orthop Sports Phys Ther 32: 510–517
Weil J et al. (1995) Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310: 827–830
Piper JM et al. (1991) Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114: 735–740
Hochain P et al. (1995) Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case–control study. Eur J Gastroenterol Hepatol 7: 419–426
Weil J et al. (2000) Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46: 27–31
Shorr RI et al. (1993) Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 153: 1665–1670
Chan FK et al. (2004) Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127: 1038–1043
Chan FK et al. (1997) Randomised trial of eradication of Helicobacter pylori before starting non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350: 975–979
Chan FK et al. (2002) Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359: 9–13
Hawkey CJ et al. (1998) Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 352: 1016–1021
Chan FK et al. (2001) Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344: 967–973
Chan FK and Leung WK (2002) Peptic-ulcer disease. Lancet 360: 933–941
Rostom A et al. (2002) Prevention of NSAID-induced gastroduodenal ulcers. The Cochrane Database of Systematic Reviews, Issue 4, Art. No CD002296
Taha AS et al. (1996) Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 334: 1435–1439
Hudson N et al. (1997) Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 112: 1817–1822
Simon TJ et al. (1994) A dose ranging study of famotidine in prevention of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs (NSAIDs): results of a US multicenter trial [abstract]. Am J Gastroenterol 89: 1644
Raskin JB et al. (1995) Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 123: 344–350
Chan FK et al. (2001) Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal hemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 15: 19–24
Hawkey CJ et al. (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338: 727–734
Yeomans ND et al. (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine Versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338: 719–726
Goldstein JL et al. (2005) Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 100: 2650–2657
Graham DY et al. (2002) Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162: 169–175
Janssen M et al. (1994) Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 39: 362–365
Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1528
Schnitzer TJ et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) reduction in ulcer complications: randomised controlled trial. Lancet 364: 665–674
Laine L et al. (2004) Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127: 395–402
Laine L et al. (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124: 288–292
Goldstein JL et al. (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3: 133–141
Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102
Solomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080
Nussmeier NA et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091
Ray WA et al. (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360: 1071–1073
Levesque LE et al. (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142: 481–489
Graham DJ et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet 365: 475–481
Solomon DH et al. (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–2073
Farkouh ME et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675–684
Johnsen SP et al. (2005) Risk of hospitalization for myocardial infarction among users of rogecoxib, celecoxib, and other NSAIDs: a population-based case–control study. Arch Intern Med 165: 978–984
Hippisley-Cox J and Coupland C (2005) Risk of myocardial infarction in patient taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case–control analysis. BMJ 330: 1366–1373
Juni P et al. (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021–2029
US Food and Drug Administration: Drug Information. COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) [http://www.fda.gov/cder/drug/infopage/cox2/default.htm] (accessed 8 August 2006)
Kearney PM et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308
National Cholesterol Education Program: third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death) [http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof] (accessed 8 August 2006)
Pearson TA et al. (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106: 388–391
MacDonald TM and Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361: 573–574
Catella-Lawson F et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–1817
Kurth T et al. (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108: 1191–1195
FitzGerald GA (2003) COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2: 879–890
Sturkenboom MC et al. (2003) Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 42 (Suppl 3): iii23–iii31
Langman MJ (2001) Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? Pharmacoepidemiol Drug Saf 10: 13–19
Mandani M et al. (2004) Gastrointestinal bleeding after the introduction of COX-2 inhibitors: ecological study. BMJ 328: 1415–1416
Malfertheiner P et al. (2002) Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 16: 167–180
Laine L et al. (2002) Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123: 1006–1012
Battistella M et al. (2005) Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 165: 189–192
Goldstein JL et al. (2003) Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States. Am J Gastroenterol 98: 2627–2634
Chan FK et al. (2006) Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis: a double blinded, randomized trial [abstract]. Gastroenterology 130: A105
Rahme E et al. (2004) Gastrointestinal effects of rofecoxib and celecoxib versus NSAIDs among patients on low-dose aspirin [abstract]. Gastroenterology 126: A155
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Chan, F. Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nat Rev Gastroenterol Hepatol 3, 563–573 (2006). https://doi.org/10.1038/ncpgasthep0610
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0610
This article is cited by
-
An interpretable boosting model to predict side effects of analgesics for osteoarthritis
BMC Systems Biology (2018)
-
Synthesis of tert-butyl (substituted benzamido)phenylcarbamate derivatives: anti-inflammatory activity and docking studies
Journal of Chemical Biology (2017)
-
Gastrodin protects against chronic inflammatory pain by inhibiting spinal synaptic potentiation
Scientific Reports (2016)
-
Arthrose
Der Internist (2015)
-
Arthrose — Was der Internist wissen sollte
CME (2015)